Freely Filtered, a NephJC Podcast

FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?

Beep Beep. Hey intern the patient’s blood pressure is 160/95. Do you want to do something. No. The answer is no. But honestly we have all been guilted into ordering some clonidine or god forbid some IV hydralazine. Stop it. Just stop it. Join the filtrate as we dissect a recent study looking at this issue with the lead author.

NephMadness prides itself on not repeating topics. Most topics don’t get revisited for years after a single appearance. But one region stands alone. One region is making its fourth appearance in the 12 year history of NephMadness! That region is Animal House! Modern medical education doesn’t go to the comparative physiology well very often. So when we do, it is always fresh and

So this one has been on the hard drive gathering dust for quite awhile. There were significant technical problems (in other words, Joel screwed up. But the episode is now complete and despite some obvious stutters, it turned out pretty good.)

The fluids wars have been going back and forth and now have another big win. This time in transplant.

On Friday of #KidneyWk, at the City Winery in Philadelphia, The Filtrate collaborated with The Curbsiders to do a live show in front of dozens of fans. Freely Filtered is proud to get to play a role in one of these moments. Amit Garg, friend of the Pod, invited Freely Filtered into the tent to record a podcast on his High Impact and Late Breaking Clinical Trial for simultaneous rel

We love Kidney Week and the quintessential event at Kidney Week is the Late Break and High Impact Clinical Trial Sessions. Here we see the cutting edge of science revealed. We get to be first when years of work are revealed to the world. And one of the coolest ways for a study to be revealed is with simultaneous publication in a high-impact journal. Freely Filtered is proud to get

Inaxaplin is a small molecule that is in trials for APOL1 associated kidney disease. Genome guided medicine comes to nephrology.

Bicarbonate did not slow the loss of GFR in this well done Swiss, single-blind study of transplant patients.The Filtrate:Joel TopfNayan AroraSwapnil HiremathPirya YenebereWith Special Guest:Nav Tangri nephrologist and epidemiology at the University of ManitobaEditor:Nayan AroraShow Notes:Arsenal FCThe London study that kicked it all off!de Brito-Ashurst, I., Varagunam, M., Raftery,

Another dogma shredding trial about diuretics, this time torsemide goes up against king furosemide and its ability to prevent rehospitalization and CV events.